Cerephex® is developing a breakthrough,
highly differentiated cortical stimulation
technology to treat central sensitivity. Our
Reduced Impedance Noninvasive Cortical
Electrostimulation (RINCE) signal is designed
to target and modulate brain function in
areas where central sensitivity is involved
Cerephex's RINCE signal technology overcomes two key technical challenges in noninvasive brain stimulation science: (1) it allows
therapeutic stimulation signals to pass through outer tissues, and (2) it provides for therapy options that target specific brain structures.
RINCE signals are imperceptible, that is, patients have reported they cannot feel the signal at all when receiving therapy.
The two images below are from a clinical research trial of RINCE signal therapy in fibromyalgia patients. The red coloring on the brain
images shows abnormal cortical function related to central sensitivity:
RINCE therapy delivered by Cerephex's NeuroPoint device was used to treat fibromyalgia patients in an independently sponsored, blinded
and controlled multicenter study. In this study, 39 fibromyalgia patients received RINCE therapy twice per week for 11 weeks. Each therapy
application took less than 20 minutes to complete, and was done in a typical physician's office environment. 38 additional patients received
a "sham" therapy. The results:
Efficacy: the entire core symptom domain specified by OMERACT for fibromyalgia studies was assessed. Endpoint measures in all
symptoms including pain and sleep demonstrated superior efficacy in the group receiving RINCE therapy compared to those receiving
sham. Over 67% of treated patients no longer met fibromyalgia classification criteria established by the American College of Rheumatology.
Safety: there were no serious adverse events in studied patients. A few patients experienced mild side effects that resolved spontaneously
without medical intervention.
Lasting Treatment Effect: follow up survey data at an average of 45-months after end of treatment demonstrate sustained symptom
improvement in a majority of treated patients, including reductions in pain, fatigue and sleep disturbance. Data also demonstrate a strong
correlation between follow up measures and end of study outcomes, suggesting that initial treatment response is predictive of a long lasting
Treatment Impact: at 45-months past end of treatment, 76% of treated patients who responded reported reduced or eliminated need for
pain medications, and 71% report reduced or eliminated need to see doctors or caregivers (see pie charts below).
Fibromyalgia patient prior to RINCE therapy
Fibromyalgia patient after RINCE therapy
These clinical study results have been presented at major medical conferences and are published in peer-reviewed medical journals. For
more information about research studies and ongoing clinical trials, please visit our Medical Professionals page.
CAUTION: NeuroPoint is an investigational device and is limited by Federal law to investigational use only. NeuroPoint is not currently
approved or cleared by the FDA.
Read more about Chronic Pain Research
Read about Cerephex's NeuroPoint Device
Return to Home Page